APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Next-Generation Tumor Genetic Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Next-Generation Tumor Genetic Testing Market Outlook and Growth Opportunities 2026

Report ID 17419734042 May 2026193 pages

Choose your research edition.

Industry ResearchNext-Generation Tumor Genetic Testing Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Next-Generation Tumor Genetic Testing Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Next-Generation Tumor Genetic Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Next-Generation Tumor Genetic Testing Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Next-Generation Tumor Genetic Testing Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Next-Generation Tumor Genetic Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Next-Generation Tumor Genetic Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Next-Generation Tumor Genetic Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Next-Generation Tumor Genetic Testing market include Devyser, Agendia, Illumina, Personal Genome Diagnostics, Veracyte, Pacific Biosciences of California, Qiagen, Agilent Technologies and Natera, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Next-Generation Tumor Genetic Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Next-Generation Tumor Genetic Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Next-Generation Tumor Genetic Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Next-Generation Tumor Genetic Testing market.

Next-Generation Tumor Genetic Testing Segment by Company

Devyser

Agendia

Illumina

Personal Genome Diagnostics

Veracyte

Pacific Biosciences of California

Qiagen

Agilent Technologies

Natera

Bio Rad Laboratories

Myriad Genetics

Next-Generation Tumor Genetic Testing Segment by Type

Fluorescence In Situ Hybridization

Polymerase Chain Reaction

Microarray Technology

Serum Proteomics

Nucleic Acid Sequencing

Next-Generation Tumor Genetic Testing Segment by Application

Hospitals

Speciality Clinics

Research Institutes

Diagnostics Laboratories

Biopharmaceutical Companies

Next-Generation Tumor Genetic Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Next-Generation Tumor Genetic Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Next-Generation Tumor Genetic Testing key companies, revenue, market share, and recent developments.

3. To split the Next-Generation Tumor Genetic Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Next-Generation Tumor Genetic Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Next-Generation Tumor Genetic Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Next-Generation Tumor Genetic Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Next-Generation Tumor Genetic Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Next-Generation Tumor Genetic Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Next-Generation Tumor Genetic Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Next-Generation Tumor Genetic Testing industry.

Chapter 3: Detailed analysis of Next-Generation Tumor Genetic Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Next-Generation Tumor Genetic Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Next-Generation Tumor Genetic Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Next-Generation Tumor Genetic Testing Industry Trends Table 2. Next-Generation Tumor Genetic Testing Industry Drivers Table 3. Next-Generation Tumor Genetic Testing Industry Opportunities and Challenges Table 4. Next-Generation Tumor Genetic Testing Industry Restraints Table 5. Global Next-Generation Tumor Genetic Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Next-Generation Tumor Genetic Testing Revenue Share by Company (2021-2026) Table 7. Global Next-Generation Tumor Genetic Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Next-Generation Tumor Genetic Testing Key Company Manufacturing Base & Headquarters Table 9. Global Next-Generation Tumor Genetic Testing Company, Product Type & Application Table 10. Global Next-Generation Tumor Genetic Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Next-Generation Tumor Genetic Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Fluorescence In Situ Hybridization Table 15. Significant Companies of Polymerase Chain Reaction Table 16. Significant Companies of Microarray Technology Table 17. Significant Companies of Serum Proteomics Table 18. Significant Companies of Nucleic Acid Sequencing Table 19. Global Next-Generation Tumor Genetic Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Next-Generation Tumor Genetic Testing Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Next-Generation Tumor Genetic Testing Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Next-Generation Tumor Genetic Testing Sales Value Share by Type (2021-2026) Table 23. Global Next-Generation Tumor Genetic Testing Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Speciality Clinics Table 26. Significant Companies of Research Institutes Table 27. Significant Companies of Diagnostics Laboratories Table 28. Significant Companies of Biopharmaceutical Companies Table 29. Global Next-Generation Tumor Genetic Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Next-Generation Tumor Genetic Testing Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Next-Generation Tumor Genetic Testing Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Next-Generation Tumor Genetic Testing Sales Value Share by Application (2021-2026) Table 33. Global Next-Generation Tumor Genetic Testing Sales Value Share by Application (2027-2032) Table 34. Global Next-Generation Tumor Genetic Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Next-Generation Tumor Genetic Testing Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Next-Generation Tumor Genetic Testing Sales Value Share by Region (2021-2026) Table 37. Global Next-Generation Tumor Genetic Testing Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Next-Generation Tumor Genetic Testing Sales Value Share by Region (2027-2032) Table 39. Global Next-Generation Tumor Genetic Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Next-Generation Tumor Genetic Testing Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Next-Generation Tumor Genetic Testing Sales Value Market Share by Country (2021-2026) Table 42. Global Next-Generation Tumor Genetic Testing Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Next-Generation Tumor Genetic Testing Sales Value Market Share by Country (2027-2032) Table 44. Devyser Company Information Table 45. Devyser Business Overview Table 46. Devyser Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Devyser Next-Generation Tumor Genetic Testing Product Portfolio Table 48. Devyser Recent Development Table 49. Agendia Company Information Table 50. Agendia Business Overview Table 51. Agendia Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Agendia Next-Generation Tumor Genetic Testing Product Portfolio Table 53. Agendia Recent Development Table 54. Illumina Company Information Table 55. Illumina Business Overview Table 56. Illumina Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Illumina Next-Generation Tumor Genetic Testing Product Portfolio Table 58. Illumina Recent Development Table 59. Personal Genome Diagnostics Company Information Table 60. Personal Genome Diagnostics Business Overview Table 61. Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Product Portfolio Table 63. Personal Genome Diagnostics Recent Development Table 64. Veracyte Company Information Table 65. Veracyte Business Overview Table 66. Veracyte Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Veracyte Next-Generation Tumor Genetic Testing Product Portfolio Table 68. Veracyte Recent Development Table 69. Pacific Biosciences of California Company Information Table 70. Pacific Biosciences of California Business Overview Table 71. Pacific Biosciences of California Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pacific Biosciences of California Next-Generation Tumor Genetic Testing Product Portfolio Table 73. Pacific Biosciences of California Recent Development Table 74. Qiagen Company Information Table 75. Qiagen Business Overview Table 76. Qiagen Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Qiagen Next-Generation Tumor Genetic Testing Product Portfolio Table 78. Qiagen Recent Development Table 79. Agilent Technologies Company Information Table 80. Agilent Technologies Business Overview Table 81. Agilent Technologies Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Agilent Technologies Next-Generation Tumor Genetic Testing Product Portfolio Table 83. Agilent Technologies Recent Development Table 84. Natera Company Information Table 85. Natera Business Overview Table 86. Natera Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Natera Next-Generation Tumor Genetic Testing Product Portfolio Table 88. Natera Recent Development Table 89. Bio Rad Laboratories Company Information Table 90. Bio Rad Laboratories Business Overview Table 91. Bio Rad Laboratories Next-Generation Tumor Genetic Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Bio Rad Laboratories Next-Generation Tumor Genetic Testing Product Portfolio Table 93. Bio Rad Laboratories Recent Development Table 94. Myriad Genetics Company Information Table 95. Myriad Genetics Business Overview Table 96. Myriad Genetics Next-Generation Tumor Genetic Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Myriad Genetics Next-Generation Tumor Genetic Testing Product Portfolio Table 98. Myriad Genetics Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Next-Generation Tumor Genetic Testing Product Image Figure 2. Global Next-Generation Tumor Genetic Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Next-Generation Tumor Genetic Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Next-Generation Tumor Genetic Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Fluorescence In Situ Hybridization Image Figure 8. Polymerase Chain Reaction Image Figure 9. Microarray Technology Image Figure 10. Serum Proteomics Image Figure 11. Nucleic Acid Sequencing Image Figure 12. Global Next-Generation Tumor Genetic Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Next-Generation Tumor Genetic Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Next-Generation Tumor Genetic Testing Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Speciality Clinics Image Figure 17. Research Institutes Image Figure 18. Diagnostics Laboratories Image Figure 19. Biopharmaceutical Companies Image Figure 20. Global Next-Generation Tumor Genetic Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Next-Generation Tumor Genetic Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Next-Generation Tumor Genetic Testing Sales Value Share by Application (2021-2032) Figure 23. Global Next-Generation Tumor Genetic Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Next-Generation Tumor Genetic Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Next-Generation Tumor Genetic Testing Sales Value (2021-2032) & (US$ Million) Figure 26. North America Next-Generation Tumor Genetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Next-Generation Tumor Genetic Testing Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Next-Generation Tumor Genetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Next-Generation Tumor Genetic Testing Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Next-Generation Tumor Genetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Next-Generation Tumor Genetic Testing Sales Value (2021-2032) & (US$ Million) Figure 32. South America Next-Generation Tumor Genetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Next-Generation Tumor Genetic Testing Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Next-Generation Tumor Genetic Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Fluorescence In Situ Hybridization
  • Polymerase Chain Reaction
  • Microarray Technology
  • Serum Proteomics
  • Nucleic Acid Sequencing
Applications
  • Hospitals
  • Speciality Clinics
  • Research Institutes
  • Diagnostics Laboratories
  • Biopharmaceutical Companies
Companies covered
  • Devyser
  • Agendia
  • Illumina
  • Personal Genome Diagnostics
  • Veracyte
  • Pacific Biosciences of California
  • Qiagen
  • Agilent Technologies
  • Natera
  • Bio Rad Laboratories
  • Myriad Genetics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Next-Generation Tumor Genetic Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Next-Generation Tumor Genetic Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Next-Generation Tumor Genetic Testing Market Dynamics
  1. 2.1 Next-Generation Tumor Genetic Testing Industry Trends
  2. 2.2 Next-Generation Tumor Genetic Testing Industry Drivers
  3. 2.3 Next-Generation Tumor Genetic Testing Industry Opportunities and Challenges
  4. 2.4 Next-Generation Tumor Genetic Testing Industry Restraints
3 Next-Generation Tumor Genetic Testing Market by Company
  1. 3.1 Global Next-Generation Tumor Genetic Testing Company Revenue Ranking in 2025
  2. 3.2 Global Next-Generation Tumor Genetic Testing Revenue by Company (2021-2026)
  3. 3.3 Global Next-Generation Tumor Genetic Testing Company Ranking (2024-2026)
  4. 3.4 Global Next-Generation Tumor Genetic Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Next-Generation Tumor Genetic Testing Company Product Type and Application
  6. 3.6 Global Next-Generation Tumor Genetic Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Next-Generation Tumor Genetic Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Next-Generation Tumor Genetic Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Next-Generation Tumor Genetic Testing Market by Type
  1. 4.1 Next-Generation Tumor Genetic Testing Type Introduction
  2. 4.1.1 Fluorescence In Situ Hybridization
  3. 4.1.2 Polymerase Chain Reaction
  4. 4.1.3 Microarray Technology
  5. 4.1.4 Serum Proteomics
  6. 4.1.5 Nucleic Acid Sequencing
  7. 4.2 Global Next-Generation Tumor Genetic Testing Sales Value by Type
  8. 4.2.1 Global Next-Generation Tumor Genetic Testing Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Next-Generation Tumor Genetic Testing Sales Value by Type (2021-2032)
  10. 4.2.3 Global Next-Generation Tumor Genetic Testing Sales Value Share by Type (2021-2032)
5 Next-Generation Tumor Genetic Testing Market by Application
  1. 5.1 Next-Generation Tumor Genetic Testing Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Speciality Clinics
  4. 5.1.3 Research Institutes
  5. 5.1.4 Diagnostics Laboratories
  6. 5.1.5 Biopharmaceutical Companies
  7. 5.2 Global Next-Generation Tumor Genetic Testing Sales Value by Application
  8. 5.2.1 Global Next-Generation Tumor Genetic Testing Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Next-Generation Tumor Genetic Testing Sales Value by Application (2021-2032)
  10. 5.2.3 Global Next-Generation Tumor Genetic Testing Sales Value Share by Application (2021-2032)
6 Next-Generation Tumor Genetic Testing Regional Value Analysis
  1. 6.1 Global Next-Generation Tumor Genetic Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Next-Generation Tumor Genetic Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Next-Generation Tumor Genetic Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Next-Generation Tumor Genetic Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Next-Generation Tumor Genetic Testing Sales Value (2021-2032)
  7. 6.3.2 North America Next-Generation Tumor Genetic Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Next-Generation Tumor Genetic Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Next-Generation Tumor Genetic Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Next-Generation Tumor Genetic Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Next-Generation Tumor Genetic Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Next-Generation Tumor Genetic Testing Sales Value (2021-2032)
  16. 6.6.2 South America Next-Generation Tumor Genetic Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Next-Generation Tumor Genetic Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Next-Generation Tumor Genetic Testing Sales Value Share by Country, 2025 VS 2032
7 Next-Generation Tumor Genetic Testing Country-level Value Analysis
  1. 7.1 Global Next-Generation Tumor Genetic Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Next-Generation Tumor Genetic Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Next-Generation Tumor Genetic Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Next-Generation Tumor Genetic Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Next-Generation Tumor Genetic Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Next-Generation Tumor Genetic Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Next-Generation Tumor Genetic Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Devyser
  2. 8.1.1 Devyser Company Information
  3. 8.1.2 Devyser Business Overview
  4. 8.1.3 Devyser Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Devyser Next-Generation Tumor Genetic Testing Product Portfolio
  6. 8.1.5 Devyser Recent Developments
  7. 8.2 Agendia
  8. 8.2.1 Agendia Company Information
  9. 8.2.2 Agendia Business Overview
  10. 8.2.3 Agendia Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Agendia Next-Generation Tumor Genetic Testing Product Portfolio
  12. 8.2.5 Agendia Recent Developments
  13. 8.3 Illumina
  14. 8.3.1 Illumina Company Information
  15. 8.3.2 Illumina Business Overview
  16. 8.3.3 Illumina Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Illumina Next-Generation Tumor Genetic Testing Product Portfolio
  18. 8.3.5 Illumina Recent Developments
  19. 8.4 Personal Genome Diagnostics
  20. 8.4.1 Personal Genome Diagnostics Company Information
  21. 8.4.2 Personal Genome Diagnostics Business Overview
  22. 8.4.3 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Personal Genome Diagnostics Next-Generation Tumor Genetic Testing Product Portfolio
  24. 8.4.5 Personal Genome Diagnostics Recent Developments
  25. 8.5 Veracyte
  26. 8.5.1 Veracyte Company Information
  27. 8.5.2 Veracyte Business Overview
  28. 8.5.3 Veracyte Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Veracyte Next-Generation Tumor Genetic Testing Product Portfolio
  30. 8.5.5 Veracyte Recent Developments
  31. 8.6 Pacific Biosciences of California
  32. 8.6.1 Pacific Biosciences of California Company Information
  33. 8.6.2 Pacific Biosciences of California Business Overview
  34. 8.6.3 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pacific Biosciences of California Next-Generation Tumor Genetic Testing Product Portfolio
  36. 8.6.5 Pacific Biosciences of California Recent Developments
  37. 8.7 Qiagen
  38. 8.7.1 Qiagen Company Information
  39. 8.7.2 Qiagen Business Overview
  40. 8.7.3 Qiagen Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qiagen Next-Generation Tumor Genetic Testing Product Portfolio
  42. 8.7.5 Qiagen Recent Developments
  43. 8.8 Agilent Technologies
  44. 8.8.1 Agilent Technologies Company Information
  45. 8.8.2 Agilent Technologies Business Overview
  46. 8.8.3 Agilent Technologies Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Agilent Technologies Next-Generation Tumor Genetic Testing Product Portfolio
  48. 8.8.5 Agilent Technologies Recent Developments
  49. 8.9 Natera
  50. 8.9.1 Natera Company Information
  51. 8.9.2 Natera Business Overview
  52. 8.9.3 Natera Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Natera Next-Generation Tumor Genetic Testing Product Portfolio
  54. 8.9.5 Natera Recent Developments
  55. 8.10 Bio Rad Laboratories
  56. 8.10.1 Bio Rad Laboratories Company Information
  57. 8.10.2 Bio Rad Laboratories Business Overview
  58. 8.10.3 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bio Rad Laboratories Next-Generation Tumor Genetic Testing Product Portfolio
  60. 8.10.5 Bio Rad Laboratories Recent Developments
  61. 8.11 Myriad Genetics
  62. 8.11.1 Myriad Genetics Company Information
  63. 8.11.2 Myriad Genetics Business Overview
  64. 8.11.3 Myriad Genetics Next-Generation Tumor Genetic Testing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Myriad Genetics Next-Generation Tumor Genetic Testing Product Portfolio
  66. 8.11.5 Myriad Genetics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst